{"id":44111,"date":"2022-05-19T13:01:13","date_gmt":"2022-05-19T11:01:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/"},"modified":"2022-05-19T13:01:13","modified_gmt":"2022-05-19T11:01:13","slug":"nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/","title":{"rendered":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting"},"content":{"rendered":"
\n

\n– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis –<\/i>\n<\/p>\n

\n– Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents –<\/i>\n<\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics<\/a>, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, today announced the presentation of new data from multiple Phase 1 clinical studies of its investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, in both healthy volunteers and patients with moderate-to-severe psoriasis. The data will be presented in a poster session at the 2022 Society for Investigative Dermatology (SID) Annual Meeting, being held May 18-21, 2022, in Portland, OR.\n<\/p>\n

<\/a><\/p>\n

\nData presented at SID reflect analyses of pharmacokinetics, pharmacodynamics, tolerability and clinical activity of NDI-034858. As previously reported<\/a>, NDI-034858 was observed to be generally well tolerated, and it showed a dose-dependent trend in exploratory clinical activity. The pharmacokinetic profile of NDI-034858 observed in healthy volunteers supports the potential for once-daily dosing, with 50 mg expected to cover IC90 for 24 hours. Additionally, an analysis of the biochemical selectivity of NDI-034858 using proprietary structure-based computational modeling found that Nimbus\u2019 TYK2 inhibitor was highly selective, with approximately 13,000 times more selectivity than deucravacitinib.\n<\/p>\n

\n\u201cNimbus\u2019 oral allosteric TYK2 inhibitor has demonstrated exceptional functional selectivity, and has an encouraging clinical activity profile and a favorable tolerability profile. Notably, there is evidence that a single amino acid difference at the allosteric binding pocket may enable greater TYK2 selectivity of NDI-034858 over deucravacitinib,\u201d said Bhaskar Srivastava, M.D., Ph.D., Senior Vice President, Clinical Development at Nimbus. \u201cThese results support continued development of this investigational drug candidate as a potential oral treatment option for patients with autoimmune diseases.\u201d\n<\/p>\n

\nThe poster, titled \u201cCharacterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in Phase 1 studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858,\u201d will be presented on Thursday, May 19, from 4:30-6:30 p.m. PT.\n<\/p>\n

\nPhase 2b clinical studies to evaluate NDI-034858 in moderate-to-severe plaque psoriasis (NCT04999839) and active psoriatic arthritis (NCT05153148) are ongoing.\n<\/p>\n

\nAbout Nimbus Therapeutics
\n
<\/b>Nimbus Therapeutics is a clinical-stage company working to design and develop breakthrough medicines through its powerful and comprehensive computational drug discovery engine. Nimbus\u2019 pipeline is comprised of multiple selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and have proven difficult for drug makers to tackle. Nimbus is headquartered in Cambridge, MA. To learn more about Nimbus, please visit www.nimbustx.com<\/a>.\n<\/p>\n

\nAbout the Nimbus TYK2 Program
\n
<\/b>TYK2 is an important signal-transducing kinase that mediates immune signaling and is important in both adaptive and innate immune cells. TYK2 inhibition is a potentially promising treatment approach for a wide range of autoimmune and inflammatory diseases due to the protein\u2019s central role in both the innate and adaptive immune responses. Nimbus is conducting a number of Phase 2 clinical studies to evaluate its novel allosteric TYK2 inhibitor, including an ongoing moderate-to-severe plaque psoriasis (NCT04999839) study and an ongoing psoriatic arthritis (NCT05153148) study. Additional trial details can be found by visiting ClinicalTrials.gov<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Chris Railey, (617) 834-0936
\n
Ten Bridge Communications
\n
chris@tenbridgecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44111","6":"format-standard","7":"category-industry"},"yoast_head":"\nNimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-19T11:01:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220519005262\/en\/796388\/21\/Nimbus_logo_RGB_NoTM.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting\",\"datePublished\":\"2022-05-19T11:01:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/\"},\"wordCount\":539,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005262\\\/en\\\/796388\\\/21\\\/Nimbus_logo_RGB_NoTM.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/\",\"name\":\"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005262\\\/en\\\/796388\\\/21\\\/Nimbus_logo_RGB_NoTM.jpg\",\"datePublished\":\"2022-05-19T11:01:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005262\\\/en\\\/796388\\\/21\\\/Nimbus_logo_RGB_NoTM.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220519005262\\\/en\\\/796388\\\/21\\\/Nimbus_logo_RGB_NoTM.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting - Pharma Trend","og_description":"– Pharmacokinetic profile supports potential for once-daily dosing in moderate-to-severe psoriasis – – Wide range of doses explore higher ranges of TYK2 inhibition in the clinic than reported by other agents – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-19T11:01:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220519005262\/en\/796388\/21\/Nimbus_logo_RGB_NoTM.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting","datePublished":"2022-05-19T11:01:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/"},"wordCount":539,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220519005262\/en\/796388\/21\/Nimbus_logo_RGB_NoTM.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/","name":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220519005262\/en\/796388\/21\/Nimbus_logo_RGB_NoTM.jpg","datePublished":"2022-05-19T11:01:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220519005262\/en\/796388\/21\/Nimbus_logo_RGB_NoTM.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220519005262\/en\/796388\/21\/Nimbus_logo_RGB_NoTM.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nimbus-therapeutics-presents-additional-clinical-data-from-phase-1-studies-of-oral-allosteric-tyk2-inhibitor-at-sid-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44111"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44111\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}